a) Industry Structure and Development
Medicamen Organics Limited was originally incorporated as "Panchdeep Pharmaceuticals Limited", a public limited Company having Corporate Identification Number (CIN) L74899DL1995PLC066416 under the provisions of the Companies Act, 1956, pursuant to a Certificate of Incorporation dated March 15, 1995, issued by the Registrar of Companies. Subsequently, pursuant to the resolutions passed by the Board of Directors on July 31, 1995 and the shareholders at the Extraordinary General Meeting held on October 14, 1995, the name of the Company was changed from "Panchdeep Pharmaceuticals Limited" to "Medicamen Organics Limited". Consequent upon the change of name, a Fresh Certificate of Incorporation dated November 14, 1995 was issued by the Registrar of Companies.
The Company is primarily engaged in the business of developing, manufacturing and distributing pharmaceutical formulations and allied products, including tablets, capsules, oral liquids, ointments, gels, syrups, suspensions and dry powders. The Company caters to government institutions, private pharmaceutical companies, contract manufacturing / third-party manufacturing arrangements and export markets. The Company continues to leverage its manufacturing capabilities, quality systems and regulatory compliance framework to serve domestic as well as international markets.
The pharmaceutical sector continues to remain an important part of Indias healthcare ecosystem and is supported by increasing healthcare awareness, growing demand for quality medicines, expanding access to healthcare services, domestic and export opportunities, and continued focus on regulatory compliance and product quality. Indias established pharmaceutical manufacturing base, availability of skilled technical manpower and cost competitiveness continue to support the long-term prospects of pharmaceutical manufacturers.
During the Financial Year under review, the Company continued to focus on strengthening its core pharmaceutical business while also pursuing strategic initiatives for product diversification and international market expansion. As part of this strategy, the Company, through its subsidiary, Grande Etoile Pharmaceuticals Limited, expanded into the beauty and personal care segment, including skincare, hair care, intimate hygiene, cosmetics and related personal care products.
The beauty and personal care segment presents growth opportunities driven by changing consumer preferences, increasing awareness regarding personal hygiene and wellness, rising demand for quality products, and growth in organised retail and digital distribution channels. The Company believes that its pharmaceutical manufacturing background, quality orientation and product development capabilities provide a foundation for exploring opportunities in this adjacent consumer healthcare and personal care segment through its subsidiary.
India continues to be recognised as a significant pharmaceutical manufacturing hub, supported by its capabilities in generic medicines, formulations, contract manufacturing, product development and cost- effective manufacturing. The pharmaceutical industry continues to benefit from domestic demand, export opportunities, regulatory developments, increasing focus on quality compliance and the need for affordable healthcare products.
The Government of India continues to support the pharmaceutical and healthcare sector through various policy initiatives, emphasis on domestic manufacturing, healthcare infrastructure development and promotion of quality and affordable medicines. These developments are expected to support long-term growth opportunities for pharmaceutical manufacturers, subject to market conditions, regulatory requirements and competitive dynamics.
Overall, the pharmaceutical industry continues to offer opportunities for companies with quality manufacturing capabilities, regulatory discipline, product development strength and efficient operations. The Company remains focused on improving operational performance, strengthening its product portfolio, enhancing customer relationships and exploring suitable domestic and international opportunities.
b) Opportunities and Threats Opportunities
The Indian pharmaceutical industry continues to present growth opportunities, supported by increasing healthcare awareness, policy support, domestic demand and expanding global opportunities. The Company expects to benefit from the following key opportunities:
a. Expansion in Government and Institutional Business: Growing procurement by Central and State Government agencies, public healthcare institutions and institutional customers presents opportunities for pharmaceutical manufacturers having their own manufacturing facilities and quality systems.
b. Growth in Export Markets: Increasing global demand for quality and cost-effective pharmaceutical products offers export opportunities. India continues to be a preferred source for generic medicines and pharmaceutical formulations, creating avenues for expansion into international markets.
c. Strengthening Manufacturing Capabilities: The Companys manufacturing infrastructure enables better control over product quality, production schedules and regulatory compliance, while supporting operational efficiencies.
d. Optimisation of Supply Chain and Inventory Management: Continued focus on efficient inventory management, improved production planning and streamlined procurement processes is expected to support operational efficiency, reduce avoidable costs and ensure timely delivery to customers.
e. Increasing Healthcare Awareness: Rising healthcare awareness, increasing penetration of healthcare services and growing demand for affordable medicines are expected to support demand for pharmaceutical products.
f. Government Support for the Pharmaceutical Sector: Policy initiatives of the Government of India, including continued emphasis on domestic manufacturing, healthcare infrastructure development and promotion of the "Make in India" initiative, are expected to support long-term industry growth.
g. Research, Product Development and Technical Expertise: Technical expertise, product development capabilities and continuous improvement in manufacturing processes provide opportunities to strengthen the Companys competitive position and expand its product portfolio.
h. Growing Domestic Market: Favourable demographic trends, increasing healthcare accessibility and rising demand for pharmaceutical products continue to support long-term prospects of the domestic pharmaceutical market.
Threats
While the long-term outlook for the pharmaceutical industry remains positive, the Company continues to monitor and address various business risks and industry challenges, including:
a. Regulatory Changes: Changes in pharmaceutical regulations, pricing policies, quality standards, environmental norms and other statutory requirements may impact business operations and compliance costs.
b. Intense Market Competition: The pharmaceutical industry remains highly competitive, with pricing pressures from domestic and international manufacturers, increasing generic competition and new market entrants.
c. Supply Chain Disruptions: Volatility in availability and pricing of raw materials, packaging materials and logistics services may affect production schedules, procurement costs and operational efficiency.
d. Dependence on Suppliers: Dependence on external vendors for certain materials or specialised requirements may expose the Company to supply disruptions and extended lead times.
e. Inventory and Working Capital Management: Fluctuations in demand, inventory obsolescence and longer receivable cycles may impact working capital requirements and operational efficiency.
f. Global Economic and Geopolitical Uncertainties: International trade restrictions, geopolitical developments, foreign exchange volatility and changes in global regulatory frameworks may affect export opportunities and business performance.
g. Quality and Regulatory Compliance Risks: The pharmaceutical industry is subject to stringent quality, manufacturing and regulatory standards. Any non-compliance or delay in obtaining regulatory approvals may adversely affect operations and business reputation.
h. Changing Market Dynamics: Evolving customer preferences, technological developments and rapidly changing market conditions require continuous improvement and timely adaptation to remain competitive.
Business vertical-wise / customer category-wise performance
The Company is primarily engaged in the pharmaceutical formulations business. For internal management review, the revenue from operations of the Company has been broadly classified into the following business verticals/customer categories:
S. No. Business vertical / customer category |
Sales (Amount in INR Lakhs) |
1 Export |
178 |
2 Government Supplies |
Nil |
3 Merchant Export |
Nil |
4 Third-party / Contract Manufacturing |
1,986.80 |
5 Other |
Nil |
Total Revenue from Operations - Standalone |
2,164.80 |
Outlook
The Company remains optimistic about the long-term growth potential of the pharmaceutical industry and is focused on strengthening its market presence through quality manufacturing, product diversification, operational excellence and customer engagement. The Company continues to leverage its manufacturing capabilities and regulatory compliance framework to cater to domestic as well as international markets while maintaining high standards of quality, safety and operational efficiency.
Going forward, the Company intends to continue strengthening its product portfolio, expanding its customer base, improving manufacturing efficiencies and optimising its supply chain to enhance operational performance and competitiveness. The Company also remains focused on exploring opportunities in export markets, while evaluating new products in line with evolving market requirements.
The Company recognises that the pharmaceutical industry operates in a dynamic regulatory and competitive environment characterised by evolving quality standards, pricing pressures, changing regulatory requirements, fluctuations in raw material costs and global supply chain challenges. Accordingly, the Company continues to strengthen its risk management framework, quality management systems and internal controls to address these challenges while ensuring sustainable business growth.
With its established manufacturing infrastructure, experienced management team, customer-centric approach and continued focus on regulatory compliance, operational excellence and quality, the Company is positioned to capitalise on emerging opportunities in domestic and international pharmaceutical markets. The management remains confident that its strategic initiatives, prudent financial management and emphasis on quality and compliance will support the Companys long-term growth and create sustainable value for stakeholders.
Risks and Concerns
The pharmaceutical industry operates in a highly regulated and competitive business environment and is exposed to various operational, financial and regulatory risks. The Company continuously evaluates these risks and has established appropriate internal control systems and risk management practices to mitigate their potential impact on its operations and long-term growth.
i. Regulatory and Compliance Risk
The pharmaceutical industry is subject to stringent regulatory requirements relating to manufacturing practices, product quality, licensing, environmental standards and product approvals. Amendments to applicable laws, regulations or regulatory expectations in India or overseas markets may impact the Companys operations, product registrations and compliance costs. The Company continuously monitors
regulatory developments and maintains quality management and compliance systems to ensure adherence to applicable statutory and regulatory requirements.
ii. Quality and Product Risk
Maintaining consistent product quality is critical to the Companys reputation and business sustainability. Any deviation from prescribed quality standards, manufacturing specifications or regulatory requirements may adversely impact the Companys operations and market reputation. The Company has implemented quality assurance and quality control systems supported by qualified personnel, manufacturing processes and periodic internal reviews to maintain quality standards.
iii. Supply Chain and Raw Material Risk
The availability and pricing of Active Pharmaceutical Ingredients (APIs), excipients, packaging materials and other critical inputs are influenced by global supply chain conditions, import dependency, logistics constraints and market volatility. Any disruption in the supply chain or significant increase in input costs may affect production schedules and profitability. The Company seeks to mitigate these risks through vendor management, procurement planning and inventory management.
iv. Market and Competitive Risk
The Indian pharmaceutical market is characterised by competition from domestic and multinational pharmaceutical companies, pricing pressure and continuous introduction of new products. Sustaining market share requires product development, competitive pricing, customer relationships and operational efficiency. The Company remains focused on expanding its product portfolio, enhancing customer engagement and maintaining product quality to strengthen its competitive position.
v. Pricing and Margin Pressure
Government policies relating to price regulation, together with increasing competition and fluctuations in raw material costs, may exert pressure on operating margins. The Company continuously focuses on cost optimisation, manufacturing efficiency and operational excellence to improve profitability.
vi. Export and Foreign Market Risk
The Companys export business is exposed to risks arising from changes in international regulatory requirements, geopolitical developments, trade restrictions, foreign exchange fluctuations and country- specific registration requirements. The Company monitors developments in its export markets and endeavours to diversify its geographical presence to reduce concentration risk.
vii. Technology and Cybersecurity Risk
Increasing digitalisation of business operations exposes organisations to cybersecurity risks, including unauthorised access, ransomware attacks, data breaches and disruption of critical systems. The Company continues to strengthen its information technology infrastructure, cybersecurity framework and data protection measures to safeguard its business operations and confidential information.
viii. Human Resource Risk
The pharmaceutical industry is knowledge-driven and dependent upon skilled professionals across manufacturing, quality assurance, research, regulatory affairs and commercial functions. The Companys continued growth depends upon its ability to attract, develop and retain competent talent. The Company remains committed to providing a safe, inclusive and performance-oriented work environment supported by employee development initiatives.
ix. Business Continuity Risk
Unexpected events such as natural disasters, pandemics, geopolitical developments, utility disruptions or other unforeseen circumstances may affect manufacturing operations, logistics and business continuity. The Company has established appropriate measures and contingency planning mechanisms to minimise operational disruptions and ensure continuity of business operations.
The Company follows a structured risk management framework under the oversight of the Board of Directors and senior management. Risks are periodically identified, assessed and reviewed, and appropriate mitigation measures are implemented to minimise their potential impact. The management believes that its governance practices, internal controls, quality systems and compliance framework adequately support the Companys objective of achieving sustainable and responsible growth.
Internal control systems and their adequacy
The Company has established an adequate and effective system of internal controls commensurate with the size, nature and complexity of its business operations. The internal control framework is designed to provide reasonable assurance regarding safeguarding of assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records, reliability of financial reporting, operational efficiency and compliance with applicable laws, regulations and internal policies.
The Companys internal control systems encompass organisational structures, standard operating procedures, delegation of authority, financial and operational controls, budgeting processes, information technology controls and compliance monitoring mechanisms. These controls are periodically reviewed and strengthened to ensure their continued effectiveness in the evolving business and regulatory environment.
The Company has an Internal Audit function, which conducts periodic audits covering key operational, financial and compliance areas. The scope of internal audit is approved by the Audit Committee, and the internal auditors submit their reports periodically, highlighting observations, if any, together with recommendations for process improvements.
The Audit Committee of the Board of Directors plays an active role in overseeing the effectiveness of the Companys internal control environment, risk management processes, internal audit function and financial reporting framework. The Committee periodically reviews the adequacy of internal financial controls, audit observations, compliance with statutory and regulatory requirements and the status of implementation of corrective actions.
The Company has also implemented internal financial controls over financial reporting to ensure that transactions are authorised, recorded and reported accurately, assets are adequately safeguarded, and Financial Statements are prepared in accordance with applicable accounting standards and regulatory requirements.
The management continuously evaluates and strengthens the internal control framework by leveraging process improvements and governance practices to enhance operational efficiency and ensure effective risk mitigation.
Based on the evaluation carried out during the year, the Board is of the opinion that the Companys internal control systems and internal financial controls are adequate and operating effectively.
Discussion on financial performance with respect to operational performance
During the Financial Year ended March 31, 2026, the Company operated in a challenging domestic and international business environment characterised by subdued market demand, competitive intensity, pricing pressures and cost trends, which adversely impacted its financial performance. Despite these challenges, the Company remained focused on strengthening operational efficiencies, maintaining product quality and regulatory compliance, while continuing to invest in strategic growth initiatives to enhance its long-term business prospects.
Revenue from operations on a standalone basis stood at INR2,164.80 lakhs during the Financial Year ended March 31, 2026, as compared to INR 3,708.77 lakhs in the previous Financial Year, representing a decline of approximately 41.63%. Consequently, the Companys total income decreased from INR 3,718.27 lakhs in the Financial Year ended March 31, 2025 to INR 2,172.04 lakhs in the Financial Year ended March 31, 2026.
The Company reported a Loss before Depreciation, Finance Cost and Tax of INR 271.13 lakhs during the Financial Year ended March 31, 2026 as against profit before Depreciation, Finance Cost and Tax of INR 563.64 lakhs in the previous Financial Year. The decline was primarily attributable to a reduction in revenue from operations coupled with operating expenditure incurred towards business development initiatives.
During the year under review, the Company, through its subsidiary, Grande Etoile Pharmaceuticals Limited, commenced its operations in Mauritius with the launch of a portfolio of cosmetics and skincare products. Initial expenditure was incurred towards business development, market entry and operational activities in connection with the expansion. These strategic initiatives, though impacting profitability during the year, are expected to strengthen the Companys international presence and support long-term business opportunities.
During the Financial Year under review, Grande Etoile Pharmaceuticals Limited, a subsidiary of the Company, also announced the full-scale commercial launch of its cosmetics, hair care, skincare and female intimate care product lines in Nepal, following a pilot phase. The said expansion forms part of the Companys broader international growth and diversification strategy in the beauty and personal care segment.
Depreciation and amortisation expense amounted to INR 88.73 lakhs as against INR 73.68 lakhs in the previous Financial Year, while finance costs increased to INR 70.58 lakhs from INR 51.27 lakhs in the Financial Year 2024-25.
Consequently, the Company reported a Loss Before Tax of INR 430.44 lakhs for the Financial Year ended March 31, 2026, as against a Profit Before Tax of INR 438.69 lakhs in the previous Financial Year. The Company reported a Loss After Tax of INR 304.54 lakhs during the Financial Year ended March 31, 2026, as compared to a Profit After Tax of INR 327.08 lakhs in the Financial Year ended March 31, 2025.
Notwithstanding the financial performance during the year, the management remains confident that the investments made towards expanding the Companys international footprint, together with continued emphasis on operational excellence, cost optimisation, product portfolio expansion and market diversification, will support sustainable growth and enhance long-term stakeholder value. The Company will continue to focus on improving manufacturing efficiencies, strengthening its domestic and export business, optimising working capital and pursuing strategic initiatives aimed at restoring profitability in the coming years.
Material developments in Human Resources / Industrial Relations front, including the number of people employed
The Company firmly believes that its employees are its valuable asset and that their knowledge, commitment and expertise are fundamental to achieving sustainable growth and operational excellence. The Company continues to focus on fostering a professional, safe and performance-oriented work environment that encourages teamwork, integrity, continuous learning and employee engagement.
During the Financial Year ended March 31, 2026, the Company continued to strengthen its human resource practices by focusing on talent retention, employee development, performance management and statutory compliance. The Company remains committed to providing equal opportunities, maintaining ethical workplace practices and ensuring compliance with applicable labour laws and employment-related regulations.
Being engaged in the pharmaceutical industry, the Company places emphasis on developing employee competencies in areas such as quality management systems, regulatory compliance, occupational health and safety, and standard operating procedures. Periodic training and awareness programmes are conducted to enhance technical capabilities, strengthen operational efficiency and promote a culture of quality and compliance across the organisation.
Industrial relations remained cordial and harmonious throughout the year. The Company continued to maintain constructive engagement with its employees, and there were no material industrial disputes or disruptions affecting business operations during the Financial Year.
As on March 31, 2026, the Company had 70 employees on its rolls. The management remains committed to nurturing a motivated and competent workforce while continuing to strengthen the organisational capabilities required to support the Companys long-term strategic objectives.
Details of significant changes in key financial ratio
Details of significant changes in key financial ratios on standalone basis, i.e., change of 25% or more as compared to the immediately previous Financial Year, in key financial ratios, along with explanations therefor, are as under:
S. No. |
Particulars |
Current Year 2025-26 |
Preceding Year 202425 |
Variance |
Comments for variation in ratios |
1 |
Current Ratio (in times) |
1.74 |
1.66 |
5.00% |
No significant change; current assets continued to exceed current liabilities. |
2 |
Debt Equity Ratio (in times) |
0.48 |
0.42 |
14.29% |
No significant change; increase mainly due to higher short-term borrowings. |
3 |
Debt Service Coverage Ratio (in times) |
-2.85 |
15.17 |
-118.79% |
Material decline due to loss before tax/operating loss during FY 2025-26 as against profit in the previous Financial Year. |
4 |
Return on Equity (%) |
-10.41% |
14.54% |
-171.60% |
Material decline due to loss after tax during FY 2025-26 as against profit after tax in FY 2024-25. |
5 |
Inventory Turnover Ratio (in times) |
1.72 |
3.15 |
-45.40% |
Material decline due to lower cost of materials consumed / revenue and higher average inventory. |
6 |
Trade Receivables Turnover Ratio (in times) |
1.02 |
1.79 |
-43.02% |
Material decline due to lower revenue and higher average trade receivables. |
7 |
Trade Payables Turnover Ratio (in times) |
1.83 |
2.37 |
-22.78% |
Change is below 25%; movement is mainly due to reduction in trade payables and cost of materials consumed. |
8 |
Net Capital Turnover Ratio (in times) |
1.43 |
2.15 |
-33.49% |
Material decline due to decrease in revenue from operations and change in working capital base. |
9 |
Net Profit Margin (%) |
-14.02% |
8.80% |
-259.32% |
Material decline due to loss after tax during FY 2025-26 as against profit after tax in FY 2024-25. |
10 |
Operating Profit Margin (%) |
-12.52% |
15.20% |
-182.37% |
Material decline due to negative operating profit before depreciation, finance costs, and tax. |
11 |
Return on Capital Employed (%) |
-8.56% |
11.92% |
-171.81% |
Material decline due to negative EBIT / loss before tax during FY 2025-26. |
There has been a material change in Return on Net Worth. Return on Net Worth stood at (10.57%) for FY 2025-26 as against 11.00% for FY 2024-25, primarily due to loss after tax during FY 2025-26.
Cautionary Statement
Statements in this Management Discussion and Analysis Report describing the Companys objectives, projections, estimates, expectations or predictions may be forward-looking statements within the meaning of applicable laws and regulations. Actual results may differ materially from those expressed or implied due to various factors, including economic conditions, market demand, availability and cost of raw materials, regulatory developments, foreign exchange fluctuations, competitive conditions, changes in government policies, tax laws and other incidental factors.
The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statement on the basis of any subsequent development, information or event.
For and on behalf of the Board of Directors of Medicamen Organics Limited
Place: New Delhi |
Place: New Delhi |
Date: August 27, 2026 |
Date: August 27, 2026 |
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.